Skip to main content

Press Releases

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

DispersinB(R) Overproduction Using a Novel Approach Published in the Journal of Industrial Microbiology & Biotechnology

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 07/21/09 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that some of its ongoing internal research on the Company's patented DispersinB® antibiofilm technology has been published in the latest online edition of the Journal of Industrial Microbiology & Biotechnology (DOI 10.1007/s10295-009-0613-0; Impact Factor: 2.0).

The publication, entitled "Enhanced expression of engineered ACA-less Beta-1,6-N-acetylglucosanimidase (dispersin B) in Escherichia coli" authored by Dr. Nandadeva Yakandawala et al, demonstrates the effectiveness of ACA-less mRNA and the advantage of GFP (Green Fluorescent Protein) tagging for enhanced DispersinB® production and quantification.

"This publication demonstrates the feasibility of commercial scale DispersinB® production using a common E. coli expression system," stated Gord Froehlich, President and CEO of Kane Biotech. "As we move towards commercialization of our technology, it is important to confirm the feasibility of cost effectively producing DispersinB®," added Mr. Froehlich.

"This study shows the versatility of the GFP tagging technique in the optimization of fermentation conditions for improving the production of DispersinB® and other proteins of commercial importance in E. coli.," stated Dr. Sri Madhyastha, VP-Research & CSO of Kane Biotech. "Furthermore, a seven-fold increase in DispersinB® production in a 30 L fermentor with minimal optimization of fermentation conditions reported in this publication shows the potential of E. coli strain overexpressing ACA-less dspB gene for commercial scale production of DispersinB® under optimized fermentation conditions."

"This is Kane's second DispersinB® antibiofilm enzyme related research publication, which adds to the growing list of publications on DispersinB® from research labs all over the world," added Dr. Madhyastha.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Kane Biotech Inc.
Gord Froehlich
President & Chief Executive Officer
204-453-1314 (FAX)